Trial Profile
A Phase II, Multicenter, Open Label, Single Arm Study of SAR302503 in Subjects Previously Treated with Ruxolitinib and with a Current Diagnosis of Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Jul 2023
Price :
$35
*
At a glance
- Drugs Fedratinib (Primary)
- Indications Essential thrombocythaemia; Myelofibrosis; Polycythaemia vera
- Focus Registrational; Therapeutic Use
- Acronyms JAKARTA2
- Sponsors Sanofi
- 15 Jun 2023 Results comparing safety outcomes using matching-adjusted indirect comparison from SIMPLIFY-1 vs JAKARTA and pooled SIMPLIFY-2 , MOMENTUM vs JAKARTA2, presented at the 28th Congress of the European Haematology Association
- 06 Jun 2023 Results of an analysis assessing (Indirect treatment comparison) ITC of safety outcomes between MMB and FED in patients with MF using data from following clinical trials: NCT04173494; NCT01969838; NCT02101268; NCT01523171; NCT01437787 presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 01 Jul 2022 Results from pooled data from JAKARTA and JAKARTA-2 studies evaluating the efficacy and safety of Fedratinib at 400mg/day dose, published in the British Journal of Haematology.